Lucid Diagnostics (LUCD) EBITDA Margin (2021 - 2026)
Lucid Diagnostics (LUCD) posted EBITDA Margin of 931.85% for Q1 2026, little changed on a QoQ basis from 935.31% in Q4 2025, and up 57625.0% year-over-year from N/an in Q1 2025.
Lucid Diagnostics (LUCD) EBITDA Margin (2021 - 2026) Analysis & Trends
Lucid Diagnostics' EBITDA Margin history runs 6 years deep, the most recent figure standing at 931.85% for Q1 2026.
- Quarterly EBITDA Margin rose 57625.0% year-over-year to 931.85% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 945.82% (up 19839.0% YoY) and the FY2025 annual result came in at 1056.17%, up 347.0% from the prior year.
- EBITDA Margin was 931.85% for Q1 2026 at Lucid Diagnostics, roughly flat from 935.31% in the prior quarter.
- Across five years, EBITDA Margin topped out at 931.85% in Q1 2026 and bottomed at 18917.11% in Q3 2022.
- A 5-year average of 3834.36% and a median of 1123.99% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin plunged 1566211 bps — and 2023, when it surged 1749590 bps.
- Lucid Diagnostics' EBITDA Margin stood at 13370.54% in 2022, then jumped by 92 bps to 1101.25% in 2023, then advanced by 6 bps to 1033.83% in 2024, then grew by 10 bps to 935.31% in 2025, then increased by 0 bps to 931.85% in 2026.
- Business Quant data shows LUCD's EBITDA Margin at 931.85% in Q1 2026, 935.31% in Q4 2025, and 971.02% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.83 Bn | 176.54 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 128.96 Bn | 126.08 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 108.62 Bn | 99.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 68.62 Bn | 67.16 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 48.35 Bn | 44.67 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 28.45 Bn | 27.33 Bn | 750.30 Mn | 21.42% |
| 7 | GE HealthCare Technologies | 28.18 Bn | 25.90 Bn | 1.98 Bn | 10.04% |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 24.68 Bn | 21.55 Bn | 2.07 Bn | 6.17% |
| 10 | Lucid Diagnostics | 127.91 Mn | 100.03 Mn | -325,000.00 | -931.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -931.85% |
| Dec 31, 2025 | -935.31% |
| Sep 30, 2025 | -971.02% |
| Jun 30, 2025 | -948.67% |
| Mar 31, 2025 | -1,508.09% |
| Dec 31, 2024 | -1,033.83% |
| Sep 30, 2024 | -997.78% |
| Jun 30, 2024 | -1,146.72% |
| Mar 31, 2024 | -1,078.12% |
| Dec 31, 2023 | -1,101.25% |
| Sep 30, 2023 | -1,421.20% |
| Jun 30, 2023 | -7,285.53% |
| Mar 31, 2023 | -3,210.09% |
| Dec 31, 2022 | -13,370.54% |
| Sep 30, 2022 | -18,917.11% |
| Mar 31, 2022 | -6,492.59% |
| Dec 31, 2021 | -3,747.00% |
| Sep 30, 2021 | -3,255.00% |